The Patent Finder

Genvivo, Inc.

11 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Epeius Biotechnologies Corporation (to 2018)

1
Ending by 2030
Apr 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 16, 2027
    The maintenance fee for Thymidine Kinase Diagnostic Assay for Gene Therapy Applications (US 10,350,302) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
  • 1 fee due Oct 7, 2027
    The maintenance fee for Thymidine Kinase Gene (US 10,610,603) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,017,659Pathotropic targeted gene delivery system for cancer and other disorders
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,350,302Thymidine Kinase Diagnostic Assay for Gene Therapy Applications
In force
 · High confidence
In forceHigh confidence
US 11,253,611Thymidine Kinase Diagnostic Assay for Gene Therapy Applications
In force
 · Low confidence
In forceLow confidence
US 11,364,307Thymidine Kinase Gene
In force
 · Low confidence
In forceLow confidence
US 9,999,683A Method for Identifying and Treating a Patient Having Tumor Lesions Comprising Administering a Gene Therapy Retroviral Vector Particle Comprising a Mutated Hsv-Thymidine Kinase (HSV-TK) Polynucleotide
In force
 · High confidence
In forceHigh confidence
US 10,610,603Thymidine Kinase Gene
In force
 · High confidence
In forceHigh confidence
US 9,925,276Thymidine Kinase Gene
In force
 · High confidence
In forceHigh confidence
US 11,992,524Compositions and methods for therapeutic or vaccine delivery
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,350,327Compositions and methods for therapeutic or vaccine delivery
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,234,475Compositions and methods for therapeutic delivery
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited